‒ Fourteen presentations highlight results from Lymphoseek® and NAV4694 clinical trials ‒ DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that data from its Lymphoseek® (technetium Tc 99m tilmanocept) Injection and NAV4694 studies are being presented at the 2013 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) to be held June 8-12, 2013 in Vancouver, Canada. In addition to the ten oral and poster presentations highlighting both the comparative performance of Lymphoseek against commonly-used non-receptor targeted colloidal materials...
↧